| scholarly article | Q13442814 |
| P50 | author | Awadhesh Kumar Singh | Q85898733 |
| P2093 | author name string | Awadhesh Kumar Singh | |
| P2860 | cites work | Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach | Q26851797 |
| SGLT2 Inhibitors May Predispose to Ketoacidosis | Q28081173 | ||
| Glucagon regulates hepatic kisspeptin to impair insulin secretion | Q30406016 | ||
| Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group compar | Q33612741 | ||
| Trends in the prevalence of ketoacidosis at diabetes diagnosis: the SEARCH for diabetes in youth study | Q33819520 | ||
| Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes | Q34453811 | ||
| Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry | Q34768952 | ||
| Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis | Q34985373 | ||
| Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis | Q35157497 | ||
| Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis | Q35784776 | ||
| Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program | Q35973246 | ||
| Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition | Q35973255 | ||
| Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes | Q36798680 | ||
| Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients | Q37524302 | ||
| SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. | Q37981884 | ||
| Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus | Q38085691 | ||
| Identity of SMCT1 (SLC5A8) as a neuron-specific Na+-coupled transporter for active uptake of L-lactate and ketone bodies in the brain | Q40262220 | ||
| A case of "pseudo-ketoacidosis". | Q41846233 | ||
| Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. | Q41895967 | ||
| Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions | Q41959585 | ||
| Regulation of glucose and ketone-body metabolism in brain of anaesthetized rats | Q42030794 | ||
| Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet | Q42974009 | ||
| Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study | Q46223922 | ||
| Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin | Q46427785 | ||
| SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats | Q46829179 | ||
| Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680-1686. | Q47646969 | ||
| Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. | Q51304272 | ||
| Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. | Q51326175 | ||
| Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. | Q51330257 | ||
| Effects of ingested fructose and infused glucagon on endogenous glucose production in obese NIDDM patients, obese non-diabetic subjects, and healthy subjects | Q71345191 | ||
| Renal tubular reabsorption of acetoacetate, inorganic sulfate and inorganic phosphate in the dog as affected by glucose and phlorizin | Q73896131 | ||
| SGLT inhibition and euglycaemic diabetic ketoacidosis | Q85258841 | ||
| Prescriber beware: report of adverse effect of sodium-glucose cotransporter 2 inhibitor use in a patient with contraindication | Q86076846 | ||
| P433 | issue | 6 | |
| P921 | main subject | glycobiology | Q899224 |
| ketoacidosis | Q1130148 | ||
| P1104 | number of pages | 9 | |
| P304 | page(s) | 722-730 | |
| P577 | publication date | 2015-11-01 | |
| P1433 | published in | Indian Journal of Endocrinology and Metabolism | Q15816442 |
| P1476 | title | Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight | |
| P478 | volume | 19 |
| Q39355218 | A Review of the Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors: A Focus on Diabetic Ketoacidosis |
| Q64930088 | Cardiac arrest from acute myocardial infarction complicated with sodium-glucose cotransporter 2 inhibitor-associated ketoacidosis. |
| Q40112887 | Clinical profile of patients with type 2 diabetes mellitus treated with sodium- glucose cotransporter-2 inhibitors and experience in real-world clinical practice in Spain |
| Q38640778 | Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences |
| Q26767260 | Dipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative review |
| Q92757967 | Enhancement of the serum chloride concentration by administration of sodium-glucose cotransporter-2 inhibitor and its mechanisms and clinical significance in type 2 diabetic patients: a pilot study |
| Q64928200 | Euglycemic diabetic ketoacidosis associated with the use of a sodium-glucose cotransporter-2 inhibitor. |
| Q38936746 | Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes |
| Q38778239 | Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature. |
| Q26752703 | Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: A systematic review of current evidence |
| Q39231122 | Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists |
Search more.